Akari Therapeutics (AKTX) Equity Ratio (2011 - 2026)

Akari Therapeutics has disclosed Equity Ratio across 16 years of filings, most recently posting 0.42 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.42, down 0.56% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.42 (down 0.56% YoY), and the FY2025 annual result was 0.59, up 34.54% from the prior year.
• Equity Ratio came in at 0.42 for Q1 2026 at Akari Therapeutics, down from 0.59 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.59 in Q4 2025 to a low of 2.45 in Q3 2024.
• The 5-year median for Equity Ratio is 0.42 (2026), against an average of 0.14.
• Across the five-year window, Equity Ratio plunged 140.61% in 2023 and jumped 936.08% in 2024, its largest moves.
• Akari Therapeutics' Equity Ratio stood at 0.13 in 2022, then sank by 140.61% to 0.05 in 2023, then jumped by 936.08% to 0.44 in 2024, then jumped by 34.54% to 0.59 in 2025, then fell by 28.26% to 0.42 in 2026.
• The last three Equity Ratio figures came in at 0.42 (Q1 2026), 0.59 (Q4 2025), and 0.5 (Q3 2025), per Business Quant data.